Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

被引：0
|
作者：
Klaus Mross
Bernward Niemann
Ulrich Massing
Joachim Drevs
Clemens Unger
Rupinder Bhamra
Christine E. Swenson
机构：
[1] Albert-Ludwigs University Freiburg,Tumor Biology Center
[2] The Liposome Company,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2004年 / 54卷
关键词：
Liposomal doxorubicin; Pharmacokinetics; Safety; Tolerability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：514 / 524
页数：10
相关论文
共 50 条
  • [1] Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors:: an open-label, single-dose study
    Mross, K
    Niemann, B
    Massing, U
    Drevs, J
    Unger, C
    Bhamra, R
    Swenson, C
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (06) : 514 - 524
  • [2] An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
    Alberto Gabizon
    Rut Isacson
    Ora Rosengarten
    Dina Tzemach
    Hilary Shmeeda
    Rama Sapir
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 695 - 702
  • [3] An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
    Gabizon, Alberto
    Isacson, Rut
    Rosengarten, Ora
    Tzemach, Dina
    Shmeeda, Hilary
    Sapir, Rama
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 695 - 702
  • [4] Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study
    Kobalava, Zhanna
    Villevalde, Svetlana
    Kotovskaya, Yulia
    Hinrichsen, Holger
    Petersen-Sylla, Marc
    Zaehringer, Andreas
    Pang, Yinuo
    Rajman, Iris
    Canadi, Jasna
    Dahlke, Marion
    Lloyd, Peter
    Halabi, Atef
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (06) : 937 - 945
  • [5] Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
    Wiebe, Sabrina
    Schnell, David
    Kuelzer, Raimund
    Gansser, Dietmar
    Weber, Anne
    Wallenstein, Gudrun
    Halabi, Atef
    Conrad, Anja
    Wind, Sven
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (03) : 461 - 469
  • [6] Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
    Sabrina Wiebe
    David Schnell
    Raimund Külzer
    Dietmar Gansser
    Anne Weber
    Gudrun Wallenstein
    Atef Halabi
    Anja Conrad
    Sven Wind
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 461 - 469
  • [7] An open-label study to evaluate dose and cycle dependence of the pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD).
    Gabizon, A.
    Isacson, R.
    Rosengarten, O.
    Tzemach, D.
    Shmeeda, H.
    Sapir, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 82S - 82S
  • [8] Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
    Kim, Seokuee
    Lee, Jongtae
    Shin, Donghoon
    Lim, Kyoung Soo
    Kim, Yon Su
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1723 - 1731
  • [9] An Open-Label Study to Evaluate the Effect of Eluxadoline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Participants
    Boinpally, Ramesh
    McGeeney, Danielle
    Kaczynski, Edward
    Weissman, Darren
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (11): : 1341 - 1348
  • [10] Effect of renal impairment on the pharmacokinetics of prucalopride: a single-dose open-label Phase I study
    Smith, William B.
    Mannaert, Erik
    Verhaeghe, Tom
    Kerstens, Rene
    Vandeplassche, Lieve
    Van de Velde, Vera
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2012, 6 : 407 - 415
12345